Thus, our findings points to the potential utility of cluster analysis to risk stratify, and this select individuals without overt heart failure or cardiovascular disease in general who may benefit from novel diabetes therapies with cardiovascular benefits, namely the SGLT-2 inhibitors [7], and the GLP-1 receptors agonists [8], which are now recommended in guidelines for use the context of diabetes, to optimize cardiovascular protection [39]. This evidence concerns the gene SLC5A2 and heart failure.